Rubedo Life Sciences is a clinical-stage biotech company focused on developing therapeutics that target the pathologic cells driving aging. The company utilizes its Alembic discovery platform to identify novel drug candidates aimed at promoting biological youthfulness. Their pipeline includes GPX4 modulators designed to address chronic diseases associated with the aging process.
Funding
$52M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic diseases are often driven by the accumulation of pathologic cells, such as senescent cells, which contribute to aging and tissue dysfunction. Current therapeutic approaches often fail to specifically target and eliminate these problematic cells, limiting their effectiveness in addressing age-related conditions.
Solution
Rubedo Life Sciences is a clinical-stage biotechnology company focused on developing targeted therapies that selectively eliminate pathologic cells responsible for driving aging and chronic diseases. The company's approach centers on modulating key pathways, such as GPX4, within these cells to promote their clearance and restore tissue homeostasis. Rubedo's lead drug candidate, RLS-1496, is a first-in-class GPX4 modulator designed to target senescent cells and surrounding tissues. Their discovery platform, ALEMBIC™, identifies relevant cell types in specific disease contexts, enabling the development of therapeutics that enhance healthspan by addressing the underlying biological mechanisms of aging.
Target Audience
The primary target audience includes individuals suffering from age-related chronic diseases, as well as pharmaceutical companies and research institutions focused on longevity and regenerative medicine.
Features
- Development of therapeutics targeting pathologic senescent cells to treat age-related diseases.
- Lead drug candidate RLS-1496, a GPX4 modulator, currently in Phase 1 clinical trials.
- ALEMBIC™ drug discovery platform for identifying senescent cells in specific disease contexts.
- Focus on restoring tissue homeostasis by eliminating dysfunctional cells.
- Multi-year partnership with Beiersdorf to develop skincare products addressing cellular aging.